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Abstract
Schizophrenia (SCZ) is a common complex disorder with poorly understood mechanisms and no 
effective drug treatments. Despite the high prevalence and vast unmet medical need represented 
by the disease, many drug companies have moved away from the development of drugs for SCZ. 
Therefore, alternative strategies are needed for the discovery of truly innovative drug treatments 
for SCZ. Here, we present a disease phenome-driven computational drug repositioning approach 
for SCZ. We developed a novel drug repositioning system, PhenoPredict, by inferring drug 
treatments for SCZ from diseases that are phenotypically related to SCZ. The key to PhenoPredict 
is the availability of a comprehensive drug treatment knowledge base that we recently constructed. 
PhenoPredict retrieved all 18 FDA-approved SCZ drugs and ranked them highly (recall = 1.0, and 
average ranking of 8.49%). When compared to PREDICT, one of the most comprehensive drug 
repositioning systems currently available, in novel predictions, PhenoPredict represented clear 
improvements over PREDICT in Precision-Recall (PR) curves, with a significant 98.8% 
improvement in the area under curve (AUC) of the PR curves. In addition, we discovered many 
drug candidates with mechanisms of action fundamentally different from traditional 
antipsychotics, some of which had published literature evidence indicating their treatment benefits 
in SCZ patients. In summary, although the fundamental pathophysiological mechanisms of SCZ 
remain unknown, integrated systems approaches to studying phenotypic connections among 
diseases may facilitate the discovery of innovative SCZ drugs.
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1. Introduction
Mental illness causes enormous personal and societal burdens [1]. In fact, mental illnesses, 
such as schizophrenia (SCZ), bipolar disease, depression and other psychiatric disorders, is 
the leading cause of impairment and disability in the United States and world-wide, 
accounting for around one-third of the disabilities in the world [2, 3]. SCZ is arguably the 
most intractable among all psychiatric disorders [4]. SCZ has a life-time prevalence of 1%, 
typically beginning before age 25 years and persisting throughout the life of the individual 
[3]. Currently, effective drugs do not exist for treating SCZ [5]. Despite the vast unmet 
medical need, many drug companies have moved away from SCZ drug development, in part 
because of the high costs, high failure rates in clinical trials, lengthy development processes, 
and a poor understanding of underlying mechanisms of the disease [5, 6, 7].
In this study, we present a computational drug repositioning approach towards discovering 
innovative drug candidates for the treatment of SCZ. Psychiatric drug discovery has 
traditionally come from repositioning existing drugs based on serendipitous clinical 
observations [8]. For example, lithium, originally approved as a sedating agent, is now used 
in the treatment of mania [9]. Chlorpromazine, originally approved as an antihistamine, is 
now used in the treatment of schizophrenia [10]. Iproniazid, originally approved as an anti-
tuberculosis agent, is now used in the treatment of depression [11]. Ketamine, originally 
approved as an anesthetic agent, has rapid antidepressant effects in patients with major 
depression [12]. Computation-based repositioning approaches that automatically reason over 
vast amounts of genetic, genomic, chemical, and phenotypic data can greatly speed up the 
timeline of traditional serendipity-based psychiatric drug discovery process and facilitate the 
identification of truly innovative drug treatments for SCZ and other psychiatric disorders 
[13, 14, 15]. However, computational drug repositioning approaches for identifying novel 
drug candidates for SCZ has not been fully explored.
Computational drug repositioning approaches can be classified as either drug-based or 
disease-based [14, 15]. Drug-based approaches leverage on the known molecular structures 
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or functions of drugs, such as chemical structures and properties, molecular docking, gene 
expression, drug treatment indications, and drug side effects [16, 17, 18, 19, 20, 21, 22, 23, 
24]. In the past 50 years, psychiatric drug discovery has been largely drug-based and has 
focused on identifying molecules with which existing drugs interact. Consequently, all 
current antidepressants, antipsychotics, and anti-anxiety drugs developed and marketed from 
the 1950s to the current day have targeted the same molecular pathways in the brain as their 
prototypes [5]. it has been recognized that drug-based discovery, with its focus on finding 
drug candidates based on existing drugs, might by definition fail to identify new therapeutic 
mechanisms [25]. An alternative approach is disease-based discovery, which puts less 
emphasis on existing drugs and focuses more on disease mechanisms and interrelationships. 
Because disease-based approaches look for similarities and interrelationships among 
diseases, these approaches are able to identify innovative drugs. Compared to drug-based 
repositioning approaches, disease-based approaches are surprisingly less explored and 
mainly used disease gene expression data [19, 20].
We hypothesize that higher-level phenotypic overlaps among diseases reflect underlying 
biological commonalities and that insights from one disease may be used to inform our 
developing knowledge of others. We developed a phenotype-driven drug repositioning 
system, PhenoPredict, to exploit drug repositioning opportunities rendered by disease 
phenotype data captured in the Human Phenotype Ontology (HPO) and a comprehensive 
drug-disease treatment relationship knowledge base (TreatKB) that we recently constructed 
[26, 27, 28]. HPO is a standardized vocabulary of phenotypic abnormalities encountered in 
human disease [29]. HPO contains phenotypic descriptions of 7,529 diseases, the majority of 
which were derived from the Online Mendelian Inheritance in Man (OMIM) [30]. Studies of 
phenotypic abnormalities in HPO have advanced our understanding of the genetic bases of 
diseases [31, 32, 33]. In a recent study, Gottlieb et al. used disease phenotypic similarities 
defined in HPO and drug-drug similarities from other databases to construct a classifier 
(PREDICT) and then used it to determine treatment associations between 593 drugs and 313 
diseases, including SCZ [34]. Different from PREDICT, PhenoPredict used a network-based 
approach to systematically exploit phenotypic interrelationships among diseases as defined 
in HPO. More importantly, PhenoPredict used a novel drug prioritization algorithm to 
exploit treatment connections among diseases as defined in TreatKB, which is a key 
component of PhenoPredict. Compared to PREDICT, our study included significantly more 
drugs and diseases (2,482 drugs and 24,511 unique disease concepts). We compared 
PhenoPredict to PREDICT in novel drug predictions using multiple evaluation datasets and 
demonstrated that PhenoPredict achieved consistently better performances.
2. Data and Methods
The experiment framework for PhenoPredict is depicted in Fig. 1 and consists of four 
phases: (1) We constructed a phenotypic disease network (PDN) using disease-disease 
similarity measures from HPO. We then developed a network-based ranking algorithm to 
find diseases that are phenotypically related to SCZ; (2) In order to validate the network 
construction and ranking algorithms of PhenoPredict and to better understand SCZ-related 
diseases, we analyzed disease class distributions among diseases at different ranking cutoffs 
and investigated what kinds of diseases were enriched among top-ranked SCZ-related 
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diseases; (3) We developed a novel drug repositioning algorithm to systematically identify 
drug repositioning candidates from SCZ-related diseases. We evaluated PhenoPredict using 
FDA-approved SCZ drugs. We compared PhenoPredict to PREDICT in novel predictions; 
and (4) In order to better understand top-ranked drug candidates, we examined drug class 
distributions among both top- and intermediate-ranked drug candidates.
2.1. Construct the phenotypic disease network (PDN) and find SCZ-related diseases from 
PDN
2.1.1. Construct phenotypic disease network (PDN)—PDN was constructed by 
directly using the disease-disease similarity matrix obtained from HPO. In HPO, individual 
diseases are often associated with multiple phenotypic terms. Similarity measures for any 
two given phenotypic terms were calculated based upon shared information content 
(frequency among annotations of all diseases) in the set of their common-ancestor nodes. 
The similarity between two diseases was then calculated by matching each phenotypic term 
of one disease with the most similar term of the other disease; the average was taken over all 
pairs of phenotypic terms [29]. We downloaded the HPO disease-disease similarity matrix 
and mapped disease terms to the Unified Medical Language System (UMLS) [35] Concept 
Unique Identifiers (CUIs) in order to facilitate the subsequent linking to drug-disease 
treatment pairs in TreatKBs that were constructed from other data sources. A total of 5708 
out of 7529 disease terms in HPO were mapped to UMLS CUIs. Instead of excluding 
unmapped terms, we used the term names as their unique identifiers. In total, we obtained 
17,523,509 disease-disease pairs, representing 7210 unique disease concepts. The similarity 
scores from the matrix were used as the edge weights of PDN. We also generated ten 
random PDNs by randomly shuffling edges of the real PDN.
2.1.2. Develop network-based ranking algorithm for finding SCZ-related 
diseases—Recently, we developed network-based approaches to prioritize genes for a 
given disease [36] and to prioritize diseases for a given microbial metabolite [37]. In this 
study, we applied these network-based algorithms to prioritize diseases for SCZ. The 
iterative network-based ranking algorithm is defined as: pt+1 = (1 − r)Mpt + rp0, wherein M 
is the column-normalized adjacency matrix of PDN, γ is a preset probability of restarting 
from the initial seed node (γ=0.1 in this study), and pt is a vector in which the ith element 
holds the normalized ranking score of disease i at tth iteration. The initial probability vector 
p0 contains normalized probability values for input. In our study, p0 contains SCZ, with a 
probability of 1.0. Diseases are ranked according to values in the steady-state probability 
vector, which is obtained by iterating the algorithm until the change between pt+1 and pt is 
less than 10−6.
2.2. Analyze disease class distribution at different ranking cutoffs
To better understand ranked diseases, we analyzed disease class distribution at ten different 
ranking cutoffs. Using SCZ as the seed, we retrieved a ranked list of 7204 diseases from 
PDN. We classified these diseases into sixteen categories using the 10th revision of the 
International Statistical Classification of Diseases and Related Health Problems (ICD10), a 
disease classification scheme designated by the World Health Organization (WHO) [38]. 
The ICD10 includes 22 highest-level disease classes (or chapters) such as “Neoplasms” and 
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“Diseases of the nervous system.” We used sixteen chapters and excluded the other six non-
specific disease classes such as “Codes for special purposes” and “Injury, poisoning and 
certain other consequences of external causes.” Because the terms used in ICD10 may differ 
from those in PDN, we expanded disease terms in ICD10 to their synonyms through UMLS 
CUIs. Disease chapters and the numbers of diseases in each chapter are listed in Table 1.
At ten ranking cutoffs (10%, 20%, … 100%), we calculated percentages of these sixteen 
disease classes among retrieved diseases. For example, at the 100% cut-off (all 7204 
retrieved diseases), 3.89% of the diseases were classified as “Mental, behavioural 
disorders.” At the 10% cutoff (top 720 diseases), 87 out of the 720 diseases (12.05%) were 
classified as “Mental, behavioural disorders,” representing a 209.8% increase as compared 
to the 100% cutoff ((12.05-3.89)/3.89 = 209.8%). This means that top-ranked diseases on 
average included more “Mental, behavioural disorders” than lower-ranked diseases. While 
this was expected and demonstrates the validity of the disease ranking algorithm, we found 
that certain other disease classes such as “Endocrine, nutritional and metabolic diseases” 
were enriched among top-ranked diseases.
2.3. Reposition drugs
2.3.1. Drug repositioning algorithm—We developed an approach to systematically 
identify drug repositioning candidates from SCZ-related diseases. We ranked drugs based on 
the number of SCZ-related diseases that they are currently approved to treat as well as the 
ranking scores of these diseases. For example, if drug 1 treats 25 top-ranked diseases, it 
would be ranked higher than drug 2, which treats only one or two lower-ranked diseases. 
The drug ranking algorithm is defined as: , wherein n is the 
number of SCZ-related diseases that are currently approved to treat and R_disease_i is the 
disease ranking score (output from the network-based disease ranking algorithm). During 
the experiment, we found that certain drugs were consistently ranked highly for both the real 
PDN and random PDNs. For example, the drug “chlordiazepoxide” was ranked at top 0.32% 
for the real PDN and on average at top 0.36% for andom PDNs. We designed our 
reprioritization strategy by accounting for rankings of a drug for random PDNs. A drug was 
ranked highly if and only if it was ranked highly based on the real PDN and the ratio of its 
ranking for the real PDN to that for random PDNs is at least 2 fold.
2.3.2. Comparison of four TreatKBs in a de-novo validation setting using 18 
known SCZ drugs as evaluation dataset—In order to systematically reposition drug 
treatments from one disease to another, it is critical to have a comprehensive drug treatment 
knowledge base. In our recent studies, we constructed four large-scale drug-disease 
treatment knowledge bases (TreatKBs) from multiple heterogeneous and complementary 
data sources using advanced computational techniques including natural language 
processing, text mining, and data mining [26, 27, 28]. The databases included 9,216 drug-
disease treatment pairs extracted from FDA drug labels, 111,862 pairs extracted from the 
FDA Adverse Event Reporting System (FAERS), a database supporting the FDA’s post-
marketing drug safety surveillance efforts, 34,306 pairs extracted from 22 million published 
biomedical literature abstracts, and 69,724 pairs extracted from 171,805 clinical trials. The 
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combined TreatKB consists of 208,330 unique drug-disease treatment pairs, representing 
2484 drugs and 24,511 unique disease concepts.
We evaluated PhenoPredict using all 18 FDA-approved SCZ drugs by comparing its 
performance across four TreatKBs. Since SCZ and its associated drug treatment pairs were 
removed from the inputs to the repositioning algorithm (SCZ-related diseases and drug-
disease treatment pairs), the evaluation is in fact a de-novo validation. We calculated the 
rankings of the 18 FDA-approved SCZ drugs among all retrieved drugs and used them as 
our gold standard. We assumed that the higher these gold standard drugs were ranked, the 
better the ranking algorithm was. We compared the performances (recall and average 
rankings) across four TreatKBs separately and in combination.
2.3.3. Compare PhenoPredict to PREDICT in novel predictions—We compared 
PhenoPredict to PREDICT in novel predictions using three evaluation datasets: (1) 195 
drugs that had been tested in SCZ clinical trials; (2) 50 drugs that were in ongoing SCZ 
clinical trials initiated in 2012 and after. These drugs may represent newer SCZ drugs; and 
(3) 114 drugs that the literature implies have been used to treat varying symptoms of SCZ. 
These three evaluation datasets were derived from TreatKBs, which was constructed from 
multiple data resources including 22 million published biomedical literature abstracts and 
171,805 clinical trials [26, 27, 28]. The 18 FDA-approved drugs were removed from these 
three evaluation datasets. Note that all SCZ-related drug treatment information were 
removed from TreatKB before PhenoPredict made predictions for SCZ.
We used Precision-Recall (PR) curves instead of Receiver Operator Characteristic (ROC) 
curves to evaluate and compare PhenoPredict to PREDICT. PR curves are often used to 
evaluate ranked classification results in information retrieval [39]. ROC curves are 
commonly used to evaluate binary classification problems in machine learning and data 
mining [40]. A PR space is defined as precision (fraction of examples classified as positive 
that are truly positive) and recall (true positive rate) as x and y axes, respectively. An ROC 
space is defined by FPR (false positive rate) and TPR (the same as recall) as x and y axes, 
respectively. Studies have shown that in domains where the number of negatives greatly 
exceeds the number of positives, such as in drug repositioning and most other biomedical 
classification domains, ROC curves can present an overly optimistic view of an algorithm’s 
performance as compared to PR curves [41, 42]. Davis et al. proved that a curve dominates 
in ROC space if and only if it dominates in PR space and algorithms that optimize the ROC 
curve are not guaranteed to optimize the PR curve [42]. Therefore, in our study, we used PR 
curves even though most biomedical classification studies use ROC curves.
PREDICT utilizes multiple drug-drug and disease-disease similarity measures for the 
prediction task [34]. PREDICT first trains a logistic regression classifier using known drug-
disease associations. It then classifies additional drug-disease associations based on their 
similarity to the known associations. We compared PhenoPredict to PREDICT in novel 
predictions. A total of 593 drugs were included in PREDICT, among which 79 drugs were 
classified as positives for SCZ. The 79 drugs along with their corresponding probabilities 
(ranging from 0.543–0.994) are publicly available [34]. The remaining 524 drugs were 
predicted by PREDICT as negatives for treating SCZ. We assigned each negative prediction 
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a value that was randomly picked from 0.0 to 0.499. We repeated this process of assigning 
values to negatives for ten iterations and generated ten datasets for PREDICT. PR curves for 
these ten datasets were similar, therefore we did not generate more datasets for PREDICT. 
The PR curves for PREDICT were then averaged across the ten datasets that we generated. 
The output from PhenoPredict is a ranked list of 2484 drugs. Using each of the three 
evaluation datasets as gold standard, we calculated precisions at 10 different recall cutoffs 
(0.1, 0.2, …; 1.0) for both PhenoPredict and PREDICT and plotted the PR curves. The area 
under curves (AUC) was used to compare the two approaches.
2.4. Analyze repositioned drug candidates
It is important to the current study, as well as to future work in the fields of computational 
drug repositioning, to better understand the nature of identified drug repositioning 
candidates. In order to facilitate such an understanding, we examined the class distributions 
of drug repositioning candidates. Drug classes were defined by the Anatomical Therapeutic 
Chemical (ATC) classification system [43]. The ATC system consists of 13 first-level 
codes, 94 second-level codes, 267 third-level codes, 882 fourth-level codes, and 4580 fifth-
level codes. The fifth-level codes are individual drugs. In our study, we used the third level 
ATC codes for the analysis. We examined top ranked drug classes for drug candidates 
ranked in the range of top 0-15% and in the range of top16-30% separately.
3. Results
3.1. Disease class analysis
Using SCZ as the seed, we retrieved a ranked list of 7204 diseases from PDN. We calculated 
percentages of sixteen disease classes among these retrieved diseases at ten different ranking 
cutoffs (10%, 20%, … 100%). Among the sixteen disease classes, three disease classes were 
enriched among top-ranked diseases: “Mental, behavioural disorders,” “Diseases of the 
nervous system,” and “Endocrine, nutritional and metabolic diseases” (Fig. 2). The increase 
for the disease class “Mental, behavioural disorders” was particularly pronounced, with a 
209.8% increase for the top 10% diseases as compared to all retrieved diseases. The 
increases for the other two classes are similar but less prominent. In summary, the 
enrichment of “Mental, behavioural disorders,” to which SCZ belongs, among top-ranked 
diseases, demonstrated the validity of our phenotype-driven network-based disease ranking 
algorithm.
3.2. FDA-approved SCZ drugs were ranked highly
When the TreatKB containing only FDA-approved drug-disease treatments was used, 
PhenoPredict achieved a recall of 0.33 and an average ranking of 30.9%. When the other 
three TreatKBs were used, PhenoPredict achieved a significantly better performance in 
terms of both recalls and rankings (Table 2). Significantly, when all four TreatKB were 
combined, PhenoPredict achieved a recall of 1.00 and an average ranking of 8.49%. These 
results demonstrate that a comprehensive TreatKB is critical component of PhenoPredict.
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3.3. PhenoPredict performed better than PREDICT in novel predictions
We plotted PR curves for PhenoPredict and PREDICT using the 195 drugs extracted from 
SCZ clinical trials as the evaluation set. The PR curve for PhenoPredict clearly dominates 
that for PREDICT. The area under the curve (AUC) for PhenoPredict is 0.489, representing 
a 98.8% improvement as compared to the AUC of 0.246 for PREDICT (Fig. 3).
When evaluated with 50 drugs extracted from ongoing SCZ clinical trials, PhenoPredic 
achieved an AUC of 0.128, representing an 81.1% improvement as compared to the AUC of 
0.071 for PREDICT (Fig. 4).
The PR curves determined using the 114 drugs that the literature implies have been used to 
treat varying symptoms of SCZ as the evaluation set are shown in Fig. 5. PhenoPredict 
achieved of an AUC of 0.289, representing a 41.2% improvement as compared to the AUC 
of 0.208 for PREDICT. In summary, PhenoPredict consistently showed improved PR curves 
compared to those for PREDICT across three different evaluation datasets.
Table 3 shows the top 20 repositioned drug candidates, all of which are implicated as 
promising candidates through evidence from sources other than our experiment, such as 
FDA drug labels, clinical trials, or biomedical literature. Among these 20 drugs, 8 are FDA-
approved drugs. These specific examples further demonstrate the potential of PhenoPredict 
in identifying promising drug repositioning candidates for SCZ.
3.4. Analysis of repositioned drug candidates offers insights to common mechanisms of 
action
The top drug candidates, those ranked in the 0-15% range, were associated with a total of 95 
third-level ATC codes. Figure 6 shows the top 15 drug classes, among which 13 classes are 
related to antipsychotics, including antidepressants, antiepileptics, and dopaminergic agents. 
We have shown in the disease class analysis that mental diseases were highly enriched 
among top-ranked diseases; therefore, it is not surprising that most of the top ranked drug 
candidates are typical antipsychotics. This result also demonstrates that common 
pathophysiologic mechanisms are shared among phenotypically related psychiatric disorders 
and that traditional psychiatric drug discovery may have fully exploited this commonality 
(i.g. the same drugs are used among related diseases).
While top ranked drugs are mainly antipsychotics, drugs with intermediate rankings may 
provide opportunities for discovering innovative drugs. Figure 7 shows the top 15 drug ATC 
codes for drugs ranked in the range of 16-30%. The majority of these top ATC codes are not 
related to antipsychotics. Evidence gleaned from the published biomedical literature shows 
that these drug classes may have treatment potential in SCZ patients. For example, two ATC 
codes “immunodepressants” and “antiinflammatory and antirheumatic” were ranked highly. 
Studies have shown that immune dysfunction and inflammation are involved in patients with 
SCZ [44, 45]. Therefore, anti-inflammatory drugs may represent promising treatments for 
SCZ. In a randomized controlled study, celecoxib, a widely used anti-inflammatory agent, 
was shown to improve symptoms experienced by SCZ patients without major side effects 
[46]. Recent genetic findings from genome-wide association studies (GWAS) also point to 
possible common genetic connections between SCZ and immune disorders [47]. Beta-
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blockers were also ranked highly. Beta blockers are commonly used to treat hypertension 
and cardiovascular diseases. Studies have shown that they may reduce anxiety and 
extrapyramidal symptoms in SCZ and have been suggested as adjunctive therapies to 
antipsychotics in SCZ or similar severe mental disorders [48, 49]. The output of 
PhenoPredict also suggests the potential use of angiotensin antagonists as an atypical SCZ 
treatment. Angiotensin antagonists are primarily used in the treatment of hypertension, 
congestive heart failure, and heart attacks. Interestingly, angiotensin has been shown to 
regulate the central nervous system activity [50, 51]. Neurochemical and anecdotal reports 
suggest that angiotensin antagonists may have mood-elevating and cognitive enhancing 
functions in patients, however mechanisms of actions by which these inhibitors modify 
cognitive performance remain unknown [52].
4. Discussion
We developed a drug repositioning system, PhenoPredict, to exploit the phenotypic 
connections among diseases and applied it to identify drug repositioning candidates for the 
treatment of SCZ. PhenoPredict ranked many traditional antipsychotic drugs highly, 
demonstrating the validity of the algorithms. In addition, we discovered many drug 
repositioning candidates with mechanisms of action fundamentally different from traditional 
antipsychotics, each of which has substantial literature-based evidence implicating its 
potential benefits in the treatment of SCZ patients. However, PR curves for PhenoPredict are 
not optimal and can certainly be improved upon with future research efforts.
First, it will be interesting to test the generalizability of PhenoPredict for other diseases. 
Currently, PhenoPredict included drug-disease treatment relationships for a total of 24,511 
diseases and 2,484 drugs. In theory, PhenoPredict can rank the 2,484 drugs for each of the 
24,511 diseases or vice versa.
Second, it will be interesting to investigate why PhenoPredict outperformed PREDICT. 
Such knowledge can offer insight into how to further improve both systems. Since the 
algorithms as well as the datasets included in both PhenoPredict and PREDICT are integral 
parts of these two systems, it is unclear which (algorithms or datasets or both) contributed to 
the PhenoPredict’s advantage over PREDICT in finding drug candidates for schizophrenia. 
It will be interesting to investigate whether integrating datasets from both PhenoPredict and 
PREDICT can further improve the performances for each system.
Third, a limitation of using disease phenotypes in HPO for drug repositioning is that HPO 
mainly includes rare Mendelian disorders, the majority of which themselves have no 
available drug treatments. Therefore, the success of PhenoPredict in identifying drug 
repositioning candidates from similar diseases to a given input disease largely depends on 
the input disease as well as the treatment availability for top-ranked diseases.
Fourth, disease genetics and genomics, in combination with disease phenotypes, may further 
facilitate the discovery of truly innovative drug candidates for SCZ. Psychiatric disorders are 
among the most heritable of all common complex diseases. Human genomics and genetics 
studies have recently identified a large number of genetic risk factors for psychiatric 
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disorders [47]. Although nearly all of the identified SCZ loci are nonspecific and not fully 
penetrant, recent GWAS studies have demonstrated shared genetic loci among 
phenotypically related psychiatric disorders including SCZ and bipolar disorder. While this 
justifies our approach of using disease phenotype data for drug repositioning, disease 
genetics and genomics may provide additional information not captured by disease 
phenotypes. However, the task of how to combining different level of evidence, including 
genetics, genomics, and phenomics, in order to build compassing predictive models for drug 
repositioning is challenging. We are actively exploring options for how to best accomplish 
this task.
Last but not least, incorporating other types of disease-phenotype relationships such as 
disease comorbidities and disease risk factors may o er additional drug repositioning 
opportunities for SCZ. Recently, we constructed three large-scale disease phenotypic 
knowledge bases, including a disease comorbidity knowledge base, a disease-risk 
relationship knowledge base, and a disease-manifestation knowledge base [27, 53, 54]. 
Unlike HPO, which includes exclusively Mendelian genetic disorders, these disease 
phenotype knowledge bases contain not only Mendelian disorders but also many common 
complex diseases. Currently, we are developing approaches to integrate disease phenotype 
knowledge from these complementary and heterogeneous data resources in an e ort to 
further improve PhenoPredict.
Acknowledgement
Xu and Wang have jointly conceived the idea, designed and implemented the algorithms. All the authors have 
participated in study discussion and manuscript preparation.
Funding
RX was supported by the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of 
the National Institutes of Health under the NIH Director’s New Innovator Award number DP2HD084068 and the 
Training grant in Computational Genomic Epidemiology of Cancer (CoGEC) (R25 CA094186-06). QW was 
partially supported by ThinTek LLC.
References
[1]. Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS, Walport M. Grand challenges in 
global mental health. Nature. 2011; 475(7354):27–30. [PubMed: 21734685] 
[2]. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month 
DSM-IV disorders in the National Comorbidity Survey Replication. Archives of general 
psychiatry. 2005; 762(6):617–627. [PubMed: 15939839] 
[3]. Mathers, C.; Fat, DM.; Boerma, JT. The global burden of disease: 2004 update. World Health 
Organization; 2008. 
[4]. Sullivan PF. Puzzling over schizophrenia: schizophrenia as a pathway disease. Nature medicine. 
2012; 18(2):210–211.
[5]. Hyman SE. Time for New Schizophrenia Rx. Science. 2014; 343(6176):1177–1177. [PubMed: 
24626901] 
[6]. Hyman SE. Revolution stalled. Science translational medicine. 2012; 4(155):155cm11–155cm11.
[7]. Miller G. Is pharma running out of brainy ideas. Science. 2010; 329(5991):502–504. [PubMed: 
20671165] 
[8]. Hyman, SE. Cerebrum: the Dana forum on brain science. Vol. 2013. Dana Foundation; Psychiatric 
Drug Development: Diagnosing a Crisis. 
Xu and Wang Page 10













[9]. Mitchell PB, Hadzi-Pavlovic D. Lithium treatment for bipolar disorder. Bulletin of the World 
Health Organization. 2000; 78(4):515–517. [PubMed: 10885179] 
[10]. Lopez-Munoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery 
and clinical introduction of chlorpromazine. Annals of Clinical Psychiatry. 2005; 17(3):113–135. 
[PubMed: 16433053] 
[11]. Maxwell, RA.; Eckhardt, SB. Drug discovery: a casebook and analysis. Humana Press; Clifton, 
NJ: p. xvii
[12]. Dolgin E. Rapid antidepressant effects of ketamine ignite drug discovery. Nature medicine. 2013; 
19(1):8–8.
[13]. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing 
drugs. Nature reviews Drug discovery. 2004; 3(8):673–683. [PubMed: 15286734] 
[14]. Dudley JT, Deshpande T, Butte AJ. Exploiting drugdisease relationships for computational drug 
repositioning. Briefings in bioinformatics. 2011; 12(4):303–311. [PubMed: 21690101] 
[15]. Hurle MR, Yang L, Xie Q, Rajpal DK, Sanseau P, Agarwal P. Computational drug repositioning: 
From data to therapeutics. Clinical Pharmacology and Therapeutics. 2013; 93(4):335–341. 
[PubMed: 23443757] 
[16]. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ. Roth BL: Predicting new 
molecular targets for known drugs. Nature. 2009; 462(7270):175–181. [PubMed: 19881490] 
[17]. Kinnings SL, Liu N, Buchmeier N, Tonge PJ, Xie L, Bourne PE. Drug discovery using chemical 
systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug 
resistant tuberculosis. PLoS computational biology. 2009; 5(7):e1000423. [PubMed: 19578428] 
[18]. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Golub TR. The Connectivity 
Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 
2006; 313(5795):1929–1935. [PubMed: 17008526] 
[19]. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A, Butte AJ. Discovery 
and preclinical validation of drug indications using compendia of public gene expression data. 
Sci Transl Med. 2011; 3(96ra):77.
[20]. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang AP, Butte AJ. Computational 
repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Science 
translational medicine. 2011; 3(96):96ra76–96ra76.
[21]. Chiang AP, Butte AJ. Systematic evaluation of drugdisease relationships to identify leads for 
novel drug uses. Clinical Pharmacology & Therapeutics. 2009; 86(5):507–510. [PubMed: 
19571805] 
[22]. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect 
similarity. Science. 2008; 321(5886):263–266. [PubMed: 18621671] 
[23]. Duran-Frigola M, Aloy P. Recycling side-effects into clinical markers for drug repositioning. 
Genome Med. 2012; 4(3)
[24]. Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, Jenkins JL, Urban L. Large-scale 
prediction and testing of drug activity on side-effect targets. Nature. 2012; 486(7403):361–367. 
[PubMed: 22722194] 
[25]. Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. Nature Neurosci. 2010; 
2010(13):1161–169. [PubMed: 20877280] 
[26]. Xu R, Wang Q. Large-scale extraction of drug-disease treatment pairs from biomedical literature 
for drug repurposing. BMC Bioinformatics. 2013; 14(1):181. [PubMed: 23742147] 
[27]. Xu R, Li L, Wang Q. Towards building a disease-phenotype relationship knowledge base: large 
scale extraction of disease-manifestation relationship from literature. Bioinformatics. 2013 doi: 
10.1093/bioinformatics/btt359. 
[28]. Xu R, Wang Q. Automatic signal prioritizing and filtering approaches in detecting post-
marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse 
Event Reporting System (FAERS). Journal of Biomedical Informatics. 2014:171–177. [PubMed: 
24177320] 
[29]. Robinson PN, Kohler S, Bauer S, Seelow D, Horn D, Mundlos S. The Human Phenotype 
Ontology: a tool for annotating and analyzing human hereditary disease. The American Journal 
of Human Genetics. 2008; 83(5):610–615. [PubMed: 18950739] 
Xu and Wang Page 11













[30]. Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA. Online Mendelian Inheritance 
in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic acids research. 
2005; 33(suppl 1):D514–D517. [PubMed: 15608251] 
[31]. Robinson PN, Kohler S, Oellrich A, Wang K, Mungall CJ, Lewis SE, Smedley D. Improved 
exome prioritization of disease genes through cross-species phenotype comparison. Genome 
research. 2014; 24(2):340–348. [PubMed: 24162188] 
[32]. Zhou X, Menche J, Barabasi AL, Sharma A. Human symptomsdisease network. Nature 
communications. 2014:5. doi:10.1038/ncomms5212. 
[33]. Moreau Y, Tranchevent LC. Computational tools for prioritizing candidate genes: boosting 
disease gene discovery. Nature Reviews Genetics. 2010; 13(8):523–536.
[34]. Gottlieb A, Stein GY, Ruppin E, Sharan R. PREDICT: a method for inferring novel drug 
indications with application to personalized medicine. Molecular systems biology. 2011; 7(1)
[35]. Bodenreider O. The unified medical language system (UMLS): integrating biomedical 
terminology. Nucleic acids research. 2004; 32(suppl 1):D267–D270. [PubMed: 14681409] 
[36]. Chen, Y.; Xu, R. Network-based Gene Prediction for Plasmodium falciparum Malaria Towards 
Genetics-based Drug Discovery; International Conference on Intelligent Biology and Medicine 
(ICIBM 2014); San Antonio, TX. Dec 4-6; 
[37]. Xu, R.; Wang, Q.; Li, L. Genome-wide systems analysis reveals strong link between colorectal 
cancer and trimethylamine N-oxide (TMAO), a gut microbial metabolite of dietary meat and fat; 
International Conference on Intelligent Biology and Medicine (ICIBM 2014); San Antonio, TX. 
Dec 4-6; 
[38]. ICD-10: International Statistical Classification of Diseases and Related Health Problems: 10th 
revision. World Health Organization; 1992. 
[39]. Manning, CD. Foundations of statistical natural language processing. Schutze, H., editor. MIT 
press; 1999. 
[40]. Provost, FJ.; Fawcett, T.; Kohavi, R. The case against accuracy estimation for comparing 
induction algorithms; International Conference on Machine Learning (ICML); 1998; p. 445-453.
[41]. Davis, J.; Burnside, ES.; de Castro Dutra, I.; Page, D.; Ramakrishnan, R.; Costa, VS.; Shavlik, 
JW. View Learning for Statistical Relational Learning: With an Application to Mammography; 
International Joint Conference on Artificial Intelligence (IJCAI); 2006; p. 677-683.
[42]. Davis, J.; Goadrich, M. The relationship between Precision-Recall and ROC curves; Proceedings 
of the 23rd international conference on Machine learning; 2005; ACM; p. 233-240.
[43]. World Health Organization. The anatomical therapeutic chemical classification system with 
defined daily doses (ATC/DDD). WHO; Norway: 
[44]. Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and 
treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. The 
International Journal of Neuropsychopharmacology. 2011; 14(07):997–1012. [PubMed: 
21156092] 
[45]. Meyer U. Anti-inflammatory signaling in schizophrenia. Brain, behavior, and immunity. 2011; 
25(8):1507–1518.
[46]. Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, Riedel M. The 
cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a 
double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Molecular 
psychiatry. 2006; 11(7):680–684. [PubMed: 16491133] 
[47]. Sullivan PF, Daly MJ, O’Donovan M. Genetic architectures of psychiatric disorders: the 
emerging picture and its implications. Nature Reviews Genetics. 2012; 13(8):537–551.
[48]. Wahlbeck K, Cheine MV, Gilbody S, Ahonen J. Efficacy of Beta-blocker supplementation for 
schizophrenia: a systematic review of randomized trials. Schizophrenia Research. 2000; 41(2):
341–7. [PubMed: 10708343] 
[49]. Shek E, Bardhan S, Cheine MV, Ahonen J, Wahlbeck K. Beta-blocker supplementation of 
standard drug treatment for schizophrenia. Schizophrenia bulletin. 2010:sbq089.
[50]. van den Buuse M, Zheng TW, Walker LL, Denton DA. Angiotensin-converting enzyme (ACE) 
interacts with dopaminergic mechanisms in the brain to modulate prepulse inhibition in mice. 
Neuroscience letters. 2005; 380(1):6–11. [PubMed: 15854741] 
Xu and Wang Page 12













[51]. Phillips IM. Functions of angiotensin in the central nervous system. Annual Review of 
Physiology. 1987; 49(1):413–433.
[52]. Domeney AM. Angiotensin converting enzyme inhibitors as potential cognitive enhancing 
agents. Journal of Psychiatry and Neuroscience. 1994; 19(1):46. [PubMed: 8148365] 
[53]. Xu R, Li L, Wang Q. dRiskKB: a large-scale disease-disease risk relationship knowledge base 
constructed from biomedical text. BMC bioinformatics. 2014; 15(1):105. [PubMed: 24725842] 
[54]. Chen Y, Zhang X, Zhang GQ, Xu R. Creation and Comparative Analysis of a Novel Disease 
Phenotype Network Based on Clinical Manifestation. Journal of Biomedical Informatics. 2014 in 
press. 
Xu and Wang Page 13














• Schizophrenia (SCZ) is among the most enigmatic disorders without curative 
drugs.
• Systems approaches to study phenotypic interconnections among diseases can 
lead novel drug discovery.
• We developed a phenome-wide systems drug repositioning approach for SCZ.
• Our approach is effective in finding FDA-approved SCZ drugs as well as in 
novel predictions.
• Our algorithm performed significantly better than one of most comprehensive 
drug repositioning system.
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The overall experimental flow chart for PhenoPredict.
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Percentages of three disease classes among 7204 diseases retrieved from HPON at ten 
ranking cutoffs (top 10%, 20%, … 100% (all diseases)). For example, ranked diseases at top 
10% cuto (top 720 diseases) contain 12.05% diseases from the class “Mental, behavioural 
disorders”. Thirteen unenriched disease classes are not shown.
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Precision-Recall curves for PhenoPredict and PREDICT using 195 drugs from SCZ clinical 
trials as gold standard.
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Precision-Recall curves for PhenoPredict and PREDICT using 50 drugs from ongoing SCZ 
clinical trials as gold standard.
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Precision-Recall curves for PhenoPredict and PREDICT using 114 drugs extracted from 
biomedical literature (MEDLINE) as gold standard.
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Top 15 third level ATC codes (out of 95 codes) and their percentages for drug candidates 
ranked in the range of 0-15%. For example, 9.94% of drugs ranked in the range of 0-15% 
belong to the class “antidepressants”.
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Top 15 third level ATC codes (out of 93 codes) and their percentages for repositioned drug 
candidates ranked in the range of 16-30%. For example, 3.31% of drugs ranked in the range 
of 16-30% belong to the class “immunosuppressants.”
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Table 1





Certain infectious and parasitic diseases 11,598 Diseases of the circulatory system 5544
Neoplasms 14,158 Diseases of the respiratory system 3156
Diseases of the blood and blood-forming organs
and certain disorders involving the immune
mechanism
3264 Diseases of the digestive system 5960
Endocrine, nutritional and metabolic diseases 5438 Diseases of the skin and subcutaneous tissue 4390
Mental and behavioural disorders 6162 Diseases of the musculoskeletal system and
connective tissue
11520
Diseases of the nervous system 5258 Diseases of the genitourinary system 5247
Diseases of the eye and adnexa 3735 Congenital malformations, deformations and
chromosomal abnormalities
9064
Diseases of the ear and mastoid process 1815 Certain conditions originating in the perinatal
period
3454
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Table 2
Comparing recalls and average rankings of 18 FDA-approved SCZ drugs for four TreatKBs individually and 
combined.
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Table 3
Top 20-ranked repositioned drug candidates. NCT**: SCZ drugs from clinical trials. PMID**: SCZ drugs 
from biomedical literature.
R Drug Evidence R Drug Evidence
1 risperidone FDA-approved 11 memantine NCT02001103
NCT00757978
NCT00097942
2 methylphenidate NCT00794040 12 buspirone NCT00178971














7 aripiprazole FDA-approved 17 levodopa NCT01636037






9 clozapine FDA-approved 19 clomipramine PMID9659874
PMID7635998
PMID7903293
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